A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
When blood amyloid levels are combined with other risk factors, people with early Alzheimer's brain changes can be identified with high accuracy.
PATH is using the tool to benchmark RDTs for several diagnostic companies and help them understand if their products are meeting competitive performance standards.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
The firm anticipates that it will soon launch the device as an in vitro diagnostic tool for analyzing tissue biopsies during surgeries in European hospitals.
Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.